drugset
drugset / Trial / NCT00488787

Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain

NCT00488787 ↗

Phase 2 Completed 40 enrolled Javelin Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3 hours post administration and assess pain intensity and pain relief throughout the 3 hour postoperative period.

Timeline

Start
2001-03
Primary completion
2001-04
Completion
2001-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 10 mg Intranasal
Subject Ketamine Small molecule 30 mg Intranasal
Subject Ketamine Small molecule 50 mg Intranasal

Indications

No indication recorded.